research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
Search
for
Sort by
Research
300-330 / 1000+ resultsresearch Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
research Treatment of Tourette’s Syndrome With Finasteride
Finasteride may effectively reduce Tourette's syndrome symptoms and improve life quality.
research P62 Pre-clinical pharmacological and skin penetration profile of LDE255, a novel and specific Smoothened antagonist
LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.
research Novel drugs of United States Food and Drug Administration approved in 2024
In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research BH04 Growing interest: a survey of low-dose oral minoxidil prescribing for hair loss
Low-dose oral minoxidil is increasingly used by dermatologists in the UK and Ireland to treat various hair loss conditions.
research Serenoa repens (saw palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part III
Saw palmetto extract is effective and safe for treating lower urinary tract symptoms, working as well as certain medications, and works even better in severe cases.
research 1. 2年間の低負荷レジスタンストレーニングが高齢者の筋機能に及ぼす効果(第134回日本体力医学会関東地方会)
Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.
research Incomplete Recovery of Erectile Function in Rat after Discontinuation of Dual 5‐Alpha Reductase Inhibitor Therapy
Rats had lasting erectile problems after stopping a certain medication.
research Signal detection between 5-alpha reductase inhibitors and the risk of suicidality and depression: an international pharmacovigilance analysis
Finasteride may increase the risk of suicidality and depression, especially in younger people.
research Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review
Low-dose oral and sublingual minoxidil seem safe for children with hair disorders.
research Alfatradiol/minoxidil/trichofoam
research Response to “Reply to effectiveness of dutasteride in a large series of patients with FFA in real clinical practice”
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
research Synthesis and structure–activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands
The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
research Trazodone associated with Clomiphene a proposal treatment for post finasteride syndrome
The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.
research Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial
research FASCE, the benefit of spironolactone for treating acne in adult females: study protocol for a randomized double-blind trial
Spironolactone is a promising alternative to antibiotics for treating acne in adult females.
research LB1101 Evaluating the cardiovascular safety of low-dose oral minoxidil in patients with non-scarring alopecia: A retrospective cohort study
Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Reply to: Oral dutasteride is a first‐line treatment for frontal fibrosing alopecia – There is insufficient evidence to recommend dutasteride as first‐line treatment in frontal fibrosing alopecia
research Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS ) With a Focus on Pericardial Effusions
Low-dose oral minoxidil can cause serious side effects like heart issues, so use the lowest effective dose.
research Treatment of localized scleroderma and lichen sclerosus with etretinate
Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.
research A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-α-Reductase in the Treatment of Androgenetic Alopecia
Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
research Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery
The new dutasteride formula can be applied to the skin, may promote hair growth, and has fewer side effects.
research Beneficial effect of spironolactone on androgenic alopecia
Spironolactone may help reduce hair loss in androgenic alopecia.
research Treatment of Androgenetic Alopecia with Low Dose Oral Minoxidil Monotherapy Compared to Combination Therapy with Dutasteride or Finasteride
Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.
research Alopecia associated with strontium ranelate use in a 62-year-old woman
A woman experienced hair loss after taking strontium ranelate for osteoporosis.
research Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
STS01 1% effectively promotes hair regrowth with minimal side effects.
research Results of stage I in a phase II randomized bilateral comparison of bexarotene 1% topical gel in alopecia areata
Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.